Merck KGaA shrinks US research team

Today's Big News

Jan 23, 2023

Theranos’ Elizabeth Holmes labeled a ‘flight risk’ as she asks to delay prison sentence during appeal 


Big Pharma set for more Senate scrutiny as Democrats eye pricing, tax probes: report 


Merck KGaA shrinks U.S. research team as layoffs continue to batter industry 


Dollar General pilots mobile clinics as it targets a bigger presence in healthcare

 

Featured

Theranos’ Elizabeth Holmes labeled a ‘flight risk’ as she asks to delay prison sentence during appeal

Prosecutors have asked a judge not to allow convicted Theranos founder Elizabeth Holmes to stay out of prison during her upcoming appeal process, citing an instance ahead of her sentencing last year where she appeared to be preparing to flee the U.S.
 

Top Stories

Big Pharma set for more Senate scrutiny as Democrats eye pricing, tax probes: report

After Republicans wrested control of the House of Representatives in November, threats of wide-ranging probes into President Joe Biden and his administration quickly followed. Now, Democrats—holding the reins of the Senate—are firing a return salvo, and the pharmaceutical industry will likely rank among the victims, Bloomberg reports.

Merck KGaA shrinks U.S. research team as layoffs continue to batter industry

Merck KGaA is laying off roughly 11% of its U.S. outpost, shrinking a Massachusetts R&D unit by more than 130 employees. The cuts come two months after executives revealed a push to be a leaner organization.

Dollar General pilots mobile clinics as it targets a bigger presence in healthcare

Discount retailer Dollar General is expanding into healthcare services in what could be a competitive shot across the bow for drugstores. The company is piloting mobile health clinics at three stores in Tennessee to provide customers with basic, preventive and urgent care services along with lab testing.

Takeda pledges up to $1.13B for rights to Hutchmed's cancer drug fruquintinib outside of China

Since the start of the decade, big pharma companies from Europe and the United States have descended on China to get in on the country’s biotech boom. The latest big pharma player to get a piece of the action however is closer to home. Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments.

Biotech may soon be defined by the 'haves and have-nots' as investors look for less risky bets

A brutal year for biotech has private investors eyeing bets with less risk and more emphasis on single assets over drug discovery engines, but there's plenty of optimism to go around in the opening weeks of 2023. 

Insulet alerts 29,000 Omnipod Dash insulin pump users to data breach linked to recall

Insulet has issued an alert for a data breach that may have compromised the health data of thousands of users of its Omnipod Dash insulin pumps.

Employers should carefully weigh benefits of high-deductible health plans: study

Workers with diabetes enrolled in high-deductible health plans face a much greater risk of being rushed to emergency departments because of hyperglycemia, says a new study. Employers need to be more judicious when weighing whether to shift employees into HDHPs.

The seer: AI tool from MIT, Mass General predicts lung cancer risk in nonsmokers 6 years out

Much like its ancient Greek namesake, a new artificial intelligence tool dubbed Sybil may be able to see into the future—though its predictions are delivered to doctors rather than to mythical gods.

Morphic loses another Big Pharma partner as J&J follows AbbVie out of the door

Morphic Therapeutic has lost another Big Pharma partner. Eleven months after AbbVie walked away, Johnson & Johnson has delivered the killer blow to its own already-diminishing ties to the biotech.

Health system CEO turnover rose in 2022 as more executives feel the strain from burnout

New reports outline trends among new CEO appointments and increasing pressure for those at the helm of hospitals and health systems.

Novartis pulls contentious claims in DTC ad campaign for breast cancer drug Kisqali but can keep similar claim for HCPs

Novartis has pulled questionable efficacy claims in a direct-to-consumer ad campaign for its breast cancer drug Kisqali after the National Advertising Division (NAD) ruled they didn’t stack up, though similar claims made to healthcare professionals can stay.
 
Fierce podcasts

Don't miss an episode

'The Top Line': Highlights from Fierce's JPM Week

This week on "The Top Line," we take you inside Fierce's JPM Week event. Listen in on snippets from a lively panel discussion on how companies will navigate the drug pricing policies the Biden administration rolled out just last year. And hear from Christine Roth, head of Bayer's oncology strategic business unit, about the company's plans to become a strong competitor in cancer.

 

Resources

Whitepaper

Reduce control arm sizes by up to 35% for Alzheimer's disease

RCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease.
Whitepaper

Quality attributes that are important for GMP-grade NTPs

What makes nucleotides suitable for current good manufacturing practices?

Whitepaper

Medical Affairs Metamorphosis V: The (R)evolution in Medical Communications

This paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series).
On-Demand Webinar

Writing the Future of Antibody Discovery Solutions

See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions.

Executive Summary

Scale-Up Strategies for Late-Stage Cell Therapies

Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more.

Whitepaper

Linear Compression vs. Parallel Processing: Speeding Biologics Through Development and Into Clinical Trials

Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more.

Whitepaper

Intranasal Drug Product Development: Formulation to Manufacturing

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?
Case Study

A Strategy to Standardize Process Characterization & Late Phase Development

Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments.

Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
 

Industry Events

 

Upcoming Fierce Events

27-28
Feb
Arlington, VA
14-15
Mar
San Francisco, CA
20-22
Mar
West Palm Beach, FL
3-4
Apr
San Diego, CA
1-3
May
May 1-3, 2023 | Jersey City, NJ

View all events